Population pharmacokinetic analysis of fluconazole to predict therapeutic outcome in burn patients with candida infection

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 2, 2013, Pages 1006-1011

  Han, Seunghoon ^a   Kim, Jimyon ^a   Yim, Haejun ^b   Hur, Jun ^b   Song, Wonkeun ^c   Lee, Jongtae ^a   Jeon, Sangil ^a   Hong, Taegon ^a   Woo, Heungjeong ^b   Yim, Dong Seok ^a  

^a The Catholic University of Korea   (South Korea)

^b Hallym University   (South Korea)

^c Kangnam Sacred Heart Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE;

ADULT; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BURN PATIENT; CANDIDIASIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; BURNS; CANDIDA; CANDIDIASIS; FEMALE; FLUCONAZOLE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; YOUNG ADULT;

EID: 84872868501     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01372-12     Document Type: Article

References (22)

1. Lipman J, Saadia R. 1997. Fungal infections in critically ill patients. BMJ 315:266-267.
2. Pittet D, Wenzel RP. 1995. Nosocomial bloodstream infections. Secular trends in rates, mortality, and contribution to total hospital deaths. Arch. Intern. Med. 155:1177-1184.
3. Nguyen MH, Peacock JE, Jr, Morris AJ, Tanner DC, Nguyen ML, Snydman DR, Wagener MM, Rinaldi MG, Yu VL. 1996. The changing face of candidemia: Emergence of non-Candida albicans species and antifungal resistance. Am. J. Med. 100:617-623.
4. Pai MP, Turpin RS, Garey KW. 2007. Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia. Antimicrob. Agents Chemother. 51:35-39.
5. Aoyama T, Hirata K, Hirata R, Yamazaki H, Yamamoto Y, Hayashi H, Matsumoto Y. 2011. Population pharmacokinetics of fluconazole after administration of fosfluconazole and fluconazole in critically ill patients. J. Clin. Pharm. Ther. doi:10.1111/j.1365-2710.2011.01297.x.
6. Berl T, Wilner KD, Gardner M, Hansen RA, Farmer B, Baris BA, Henrich WL. 1995. Pharmacokinetics of fluconazole in renal failure. J. Am. Soc. Nephrol. 6:242-247.
7. Debruyne D. 1997. Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses. Clin. Pharmacokinet. 33:52-77.
8. Boucher BA, King SR, Wandschneider HL, Hickerson WL, Hanes SD, Herring VL, Canada TW, Hess MM. 1998. Fluconazole pharmacokinetics in burn patients. Antimicrob. Agents Chemother. 42:930-933.
9. Debruyne D, Ryckelynck JP. 1993. Clinical pharmacokinetics of fluconazole. Clin. Pharmacokinet. 24:10-27.
10. Verbeeck RK, Musuamba FT. 2009. Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur. J. Clin. Pharmacol. 65: 757-773.
11. Rayatt S, Wienbren M, Clarke J. 2000. Fluconazole use in burns patients. Burns 26:109-110.
12. Hannon RA, Pooler C, Porth C. 2009. Porth pathophysiology: Concepts of altered health states. Lippincott Williams & Wilkins, Philadelphia, PA.
13. Hart DW, Wolf SE, Mlcak R, Chinkes DL, Ramzy PI, Obeng MK, Ferrando AA, Wolfe RR, Herndon DN. 2000. Persistence of muscle catabolism after severe burn. Surgery 128:312-319.
14. European Committee on Antimicrobial Susceptibility Testing. 2007. EUCAST fluconazole rationale document version 1.0. http://www.eucast .org/fileadmin/src/media/PDFs/EUCAST-files/Rationale-documents/Fl uconazole-rationale-document-1.0-final.pdf.
15. Pfizer. 2011. Diflucan (fluconazole tablets). Pfizer Inc., New York, NY. http: //www.accessdata.fda.gov/drugsatfda-docs/label/2011/019949s051lbl.pdf.
16. Chin T, Fong IW, Vandenbroucke A. 1990. Pharmacokinetics of fluconazole in serum and cerebrospinal fluid in a patient with AIDS and cryptococcal meningitis. Pharmacotherapy 10:305-307.
17. Foulds G, Brennan DR, Wajszczuk C, Catanzaro A, Garg DC, Knopf W, Rinaldi M, Weidler DJ. 1988. Fluconazole penetration into cerebrospinal fluid in humans. J. Clin. Pharmacol. 28:363-366.
18. Pittrow L, Penk A. 1999. Special pharmacokinetics of fluconazole in septic, obese and burn patients. Mycoses 42:S87-S90.
19. Ulldemolins M, Roberts JA, Rello J, Paterson DL, Lipman J. 2011. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin. Pharmacokinet. 50:99-110.
20. Andes D. 2003. In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis. Antimicrob. Agents Chemother. 47:1179-1186.
21. Rex JH, Pfaller MA, Galgiani JN, Bartlett MS, Espinel-Ingroff A, Ghannoum MA, Lancaster M, Odds FC, Rinaldi MG, Walsh TJ, Barry AL. 1997. Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Clin. Infect. Dis. 24:235-247.
22. Mouton JW. 2007. Pharmacokinetics and pharmacodynamics of azoles, p 327-354. In Nightingale CH, Ambrose PG, Drusano DL, Murakawa T (ed), Antimicrobial pharmacodynamics in theory and clinical practice, 2nd ed. Informa Healthcare, New York, NY.